Human metapneumovirus
Metapneumovirus A and B
General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.
Overview
An RNA virus related to RSV, causing late-winter and spring respiratory illness.
Infections
Upper respiratory infection, bronchiolitis, pneumonia; outbreaks in long-term care.
Signs and symptoms
Cough, fever, nasal congestion, wheeze, shortness of breath.
Antibiotic and antimicrobial resistance
No antiviral is used, so drug resistance is not a clinical issue. Antibiotics do not act on viruses; identifying a viral cause can support withholding them.
Treatment considerations
Supportive care: fluids, fever control and oxygen when needed. No antiviral is approved. Antibiotics are reserved for a confirmed or strongly suspected bacterial co-infection.
Infection control and public health
Contact and droplet precautions.
Sources
- CDC. Human metapneumovirus.
Sources accessed November 2026. Links open external sites that InnovexLab does not control.
Medical disclaimer
This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.
Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.